ArticleBritish journal of cancer1999
Allele loss and mutation screen at the Peutz-Jeghers (LKB1) locus (19p13.3) in sporadic ovarian tumours.
Article in British journal of cancer, 1999. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 79 citations in OpenAlex.
- Metabolic collateral lethal target identification reveals MTHFD2 paralogue dependency in ovarian cancer.Nature metabolism · 2022Article
- Review
- From somatic mutation to early detection: insights from molecular characterization of pancreatic cancer precursor lesions.The Journal of pathology · 2018Review
- RNF126 as a Biomarker of a Poor Prognosis in Invasive Breast Cancer and CHEK1 Inhibitor Efficacy in Breast Cancer Cells.Clinical cancer research : an official journal of the American Association for Cancer Research · 2018Article
- Functional redundancy between Apc and Apc2 regulates tissue homeostasis and prevents tumorigenesis in murine mammary epithelium.Oncogene · 2017Article
- RNF126 promotes homologous recombination via regulation of E2F1-mediated BRCA1 expression.Oncogene · 2016Article
- Decreased LKB1 predicts poor prognosis in Pancreatic Ductal Adenocarcinoma.Scientific reports · 2015Article
- Rewiring cell polarity signaling in cancer.Oncogene · 2015Review
- Liver kinase B1 enhances chemoresistance to gemcitabine in breast cancer MDA-MB-231 cells.Oncology letters · 2014Article
- SWI/SNF chromatin remodeling complexes and cancer.American journal of medical genetics. Part C, Seminars in medical genetics · 2014Review
- The tumor suppressor LKB1 antagonizes WNT signaling pathway through modulating GSK3β activity in cell growth of esophageal carcinoma.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2014Article
- Dysregulation of mTOR activity through LKB1 inactivation.Chinese journal of cancer · 2013Review
- Tumor-derived mutations in the gene associated with retinoid interferon-induced mortality (GRIM-19) disrupt its anti-signal transducer and activator of transcription 3 (STAT3) activity and promote oncogenesis.The Journal of biological chemistry · 2013Article
- Potential contribution of SIM2 and ETS2 functional polymorphisms in Down syndrome associated malignancies.BMC medical genetics · 2013Article
- Immunohistological evidence for Wnt-signaling activation in Peutz-Jeghers polyposis.Pediatric surgery international · 2010Article
- Hijacking the chromatin remodeling machinery: impact of SWI/SNF perturbations in cancer.Cancer research · 2009Review
- The new molecular biology of granulosa cell tumors of the ovary.Genome medicine · 2009Article
- Clinical significance of the reduced expression of G protein gamma 7 (GNG7) in oesophageal cancer.British journal of cancer · 2008Article
- Review
- Overexpression of SERTAD3, a putative oncogene located within the 19q13 amplicon, induces E2F activity and promotes tumor growth.Oncogene · 2007Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 7 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Germline mutations in the LKB1 (STK11) gene (chromosome sub-band 19p13.3) cause characteristic hamartomas and pigmentation to develop in patients with Peutz-Jeghers syndrome. Peutz-Jeghers syndrome carries an overall risk of cancer that may be up to 20 times that of the general population and Peutz-Jeghers patients are at increased risk of benign and malignant ovarian tumours, particularly granulosa cell tumours. Loss of heterozygosity (allele loss, LOH) has been reported in about 50% of ovarian cancers on 19p13.3. LKB1 is therefore a candidate tumour suppressor gene for sporadic ovarian tumours. We found allele loss at the marker D19S886 (19p13.3) in 12 of 49 (24%) sporadic ovarian adenocarcinomas. Using SSCP analysis, we screened ten ovarian cancers with LOH, 35 other ovarian cancers and 12 granulosa cell tumours of the ovary for somatic mutations in LKB1. No variants were detected in any of the adenocarcinomas. Two mutations were detected in one of the granulosa cell tumours: a mis-sense mutation affecting the putative 'start' codon (ATG --> ACG, M1T); and a silent change in exon 7 (CTT --> CTA, leucine). Like BRCA1 and BRCA2, therefore, it appears that LKB1 mutations can cause ovarian tumours when present in the germline, but occur rarely in the soma. The allele loss on 19p13.3 in ovarian cancers almost certainly targets a different gene from LKB1.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.